Fuzzy-Based Application Model and Profile Matching for Recommendation Suitability of Type 2 Diabetic
Abstract
Keywords
Full Text:
PDFReferences
WHO, “Global Report on Diabetes,†France, 2016.
ADA, “Classi fi cation and Diagnosis of Diabetes: Standards of Medical Care in Diabetes d 2020,†Care.diabetesjournals.org, vol. 43, no. January, pp. 14–31, 2020.
IDF, “International Diabetes Federation - Type 2 diabetes,†International Diabetes Federation, 2019. [Online]. Available: https://www.idf.org/aboutdiabetes/type-2-diabetes.html. [Accessed: 03-Apr-2020].
PERKENI, “Pedoman Pengelolaan dan Pencegahan Diabates Melitus Tipe 2 Dewasa,†in Pedoman Pengelolaan dan Pencegahan Diabates Melitus Tipe 2 Dewasa di Indonesia, Pertama De., D. Lindarto, Ed. Jakarta: PB PERKENI, 2019, pp. 1–132.
A. J. Garber et al., “Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary,†Endocr. Pract., vol. 26, no. 1, pp. 107–139, 2020.
N. D. DiPiro et al., “Lower extremity strength is correlated with walking function after incomplete SCI,†Top. Spinal Cord Inj. Rehabil., vol. 21, no. 2, pp. 133–139, 2015.
Y. Handelsman et al., “American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015,†Endocrine Practice, vol. 21, no. April. pp. 1–87, 2015.
Diabetes UK, “Our story Annual report and accounts 2018 Contents,†UK, 2018.
Anonim, “Royal Pharmaceutical Society of Great Britain,†Br. Med. Assoc., vol. 52, no. 116–117, pp. 1–12, 2006.
J. Thrasher, “Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies,†Am. J. Cardiol., vol. 120, no. 1, pp. S4–S16, 2017.
D. Bina et al., Pharmaceutical care untuk penyakit diabetes mellitus, Second. Jakarta: Bina Kefarmasian dan Alat Kesehatan, 2005.
R. C. Chen, Y. H. Huang, C. T. Bau, and S. M. Chen, “A recommendation system based on domain ontology and SWRL for antidiabetic drugs selection,†Expert Syst. Appl., vol. 39, no. 4, pp. 3995–4006, 2012.
S. M. Chen, Y. H. Huang, and R. C. Chen, “A recommendation system for antidiabetic drugs selection based on fuzzy reasoning and ontology techniques,†Int. J. Pattern Recognit. Artif. Intell., vol. 27, no. 4, 2013.
R. C. Chen, H. Q. Jiang, C. Y. Huang, and C. T. Bau, “Clinical Decision Support System for Diabetes Based on Ontology Reasoning and TOPSIS Analysis,†J. Healthc. Eng., vol. 2017, pp. 9–12, 2017.
PERKENI, “Pengelolaan dan Pengobatan Diabetes Melitus Tipe 2 Dewasa,†in Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia, Pertama., vol. 1, D. D. S. A. Soelistijo, Ed. Jakarta: PB PERKENI, 2019, p. 132.
H. Soetanto, S. Hartati, R. Wardoyo, and S. Wibowo, “Hypertension drug suitability evaluation based on patient condition with improved profile matching,†Indones. J. Electr. Eng. Comput. Sci., 2018.
Kemenkes RI, “Modul Penggunaan Obat Rasional,†kemenkes RI, pp. 3–8, 2011.
American Diabetes Association, “Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020,†Diabetes care, vol. 43, no. January. pp. S98–S110, 2020.
Diabetes Federation International, IDF Diabetes Atlas Ninth edition 2019. 2019.
F. R. Guilherme, C. A. Molena-Fernandes, V. R. Guilherme, M. T. M. Fávero, E. J. B. dos Reis, and W. Rinaldi, “Body mass index, waist circumference, and arterial hypertension in students,†Rev. Bras. Enferm., vol. 68, no. 2, pp. 190–194, 2015.
P. Pendidikan, D. Spesialis, P. Klinik, R. Sakit, and H. Sadikin, “Pemeriksaan Fungsi Ginjal,†CKD-237, vol. 43, no. 2, pp. 148–154, 2016.
S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, “The time is right for a new classification system for diabetes: Rationale and implications of the β-cell-centric classification schema,†Diabetes Care, vol. 39, no. 2, pp. 179–186, 2016.
C. Prontera et al., “Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study,†vol. 47, no. January 2005, pp. 762–768, 2009.
D. Care and S. S. Suppl, “9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetesd2019,†Diabetes Care, vol. 42, no. January, pp. S90–S102, 2019.
J. Dolenšek, M. S. Rupnik, and A. Stožer, “Structural similarities and differences between the human and the mouse pancreas,†Islets, vol. 7, no. 1, 2015.
H. Marcovitch, Black’s Medical Dictionary, 41st ed. London: A & C Black, 2005.
H. Ari Suhartanto, Kusrini, “Decision Support System Untuk Penilaian Kinerja Guru Dengan Metode Profile Matching,†J. Komput. Terap., vol. 2, no. 2, pp. 149–158, 2016.
H. P. Sri Kusuma Dewi, Aplikasi Logika Fuzzy untuk Pendukung Keputusan, Kedua., vol. Kedua. Yogyakarta: Graha Ilmu, 2010.
P. Made and S. D. Pathni, “Terapi Diabetes dengan SGLT-2 Inhibitor,†vol. 46, no. 6, pp. 452–456, 2019.
I. Saritas, I. A. Ozkan, and N. Allahverdi, “Determination of the drug dose by fuzzy expert system in treatment of chronic intestine inflammation Determination of the drug dose by fuzzy expert system,†J Intell Manuf Springer, no. April, p. 9, 2009.
M. Eghbali-Zarch, R. Tavakkoli-Moghaddam, F. Esfahanian, M. M. Sepehri, and A. Azaron, “Pharmacological therapy selection of type 2 diabetes based on the SWARA and modified MULTIMOORA methods under a fuzzy environment,†Artif. Intell. Med., vol. 87, pp. 20–33, 2018.
M. Al Switi, B. Alshraideh, A. Alshraideh, A. Massad, and M. Alshraideh, “Treatment of diabetes type II using genetic algorithm,†Int. J. online Biomed. Eng., vol. 15, no. 11, pp. 53–68, 2019.
L. Qin and V. Atluri, “Evaluating the validity of data instances against ontology evolution over the Semantic Web,†Inf. Softw. Technol., vol. 51, no. 1, pp. 83–97, 2009.
DOI: http://dx.doi.org/10.18517/ijaseit.11.3.12277
Refbacks
- There are currently no refbacks.
Published by INSIGHT - Indonesian Society for Knowledge and Human Development